Switching hemophilia a patients to an extended half-life agent on a prophylactic basis: an economic appraisal
{{output}}
Background: Gaining an understanding of transitioning hemophilia patients to an extended half-life (EHL) agent requires real-world data, encompassing various outcomes, which would help assessing the impact of the switch, for pati... ...
